MAXCYTE, INC.

Share Issue/Capital Change • Feb 28, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3007G

MaxCyte, Inc.

28 February 2018

MaxCyte, Inc.

("MaxCyte" or the "Company")

Director Dealings

Maryland, USA, 28 February 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that J. Stark Thompson, Non-Executive Chairman of the Company, has sold 24,000 shares of common stock of 0.1 pence each in the capital of the Company ("Common Stock") at a price of 246 pence per Common Stock for the purpose of funding a near term personal tax liability. Dr Thompson has no current intention of making further sales of MaxCyte shares.

Following the sale, J. Stark Thompson holds a total of 110,918 Common Stock representing a total of 0.2% of the issued share capital of the Company and a further 213,633 options over common stock.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	J. Stark Thompson
2	Reason for the notification
a)	Position/status	Non-Executive Chairman and PDMR
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Sale of Common Stock
b)	Identification Code	US57777K1060
c)	Nature of the transaction	Sale of Common Stock by PDMR
d)	Price(s) and volume(s)	Price(s)	Volume(s)
246.00 pence	24,000
e)	Aggregated information - Aggregated volume - Price	N/A (Single Transaction) 24,000 246.00
f)	Date of the transaction	28 February 2018
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

For further information, please contact:

MaxCyte Inc.
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer	+1 301 944 1660
Nominated Adviser and Broker Panmure Gordon
Freddy Crossley (Corporate Finance) Ryan McCarthy Tom Salvesen (Corporate Broking)	+44 (0) 20 7886 2500
Financial PR Adviser Consilium Strategic Communications
Mary-Jane Elliott Chris Welsh Suki Virji	+44 (0)203 709 5700 [email protected]

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering enabling technology to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery technology, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This technology allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering enabling technology is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumours where existing CAR-T approaches face significant challenges.   For more information, visit http://www.maxcyte.com/.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEAKAPASPPEFF